Be the first person to write a business review for Helicos BioSciences Corporation

Hi-Tech Pharmacal Co., Inc. was founded in 1982 and is based in Amityville, New York. Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and OTC brands. It produce a range of products for various disease states, including asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, neurological disorders, glaucoma and other conditions. The Company’s generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments, as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. On February 27, 2009, the Company purchased substantially all of the assets of E. Claiborne Robins Company, Inc. doing business as, ECR Pharmaceuticals (ECR Pharmaceuticals or ECR).

Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

K-V Pharmaceutical Company (KV) is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. KV conducts its branded pharmaceutical operations through Ther-Rx Corporation (Ther-Rx) and its generic/non-branded pharmaceutical operations through ETHEX Corporation (ETHEX). Through Particle Dynamics, Inc. (PDI), the Company also develops, manufactures and markets value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. The Company has developed a variety of drug delivery and formulation technologies, which are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release, and oral quick dissolving tablets.

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The Company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The Company’s subsidiaries include Doctor Morepen Limited, Total Care Limited, Morepen Inc. and MorepenMax Inc.

Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania. Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan’s products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA’s Central & Eastern Europe (CEE) generics businesses.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.